Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
Shares of Eidos Therapeutics closed up 6.1% at $37.32 yesterday, after it was revealed that, under a non-binding proposal, BridgeBio Pharma will purchase all of the outstanding common stock of the company not already owned. 13 August 2019
Biotechnology
A trial of the Regeneron Pharmaceuticals Ebola virus drug REGN-EB3 has been stopped early because it showed superiority to Mapp Biopharmaceutical’s rival, ZMapp. 12 August 2019
Biotechnology
Swiss biotech AC Immune has supplemented its research efforts in neurodegenerative diseases with a newly-announced partnership with the University of Pennsylvania (Penn). 12 August 2019
Biotechnology
China and Boston, USA-based biotech firm Oncologie has entered into a clinical collaboration with Merck & Co (NYSE: MRK) to evaluate the combination of its investigational drug bavituximab, an antibody that blocks the activity of phosphatidylserine (PS), and Merck's blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with advanced gastric or gastroesophageal cancer. 12 August 2019
Biotechnology
The announcement of a new submission of a Biologics License Application (BLA) for Viaskin Peanut was hailed by DBV Technologies as a major milestone for the company. 12 August 2019
Biotechnology
Chinese biotech firm Ascletis Pharma over the weekend opened its Clinical Development Shanghai Center, signalling the further expansion of R&D capability, especially in oncology and non-alcoholic steatohepatitis (NASH). 12 August 2019
Biotechnology
UK biotech Circassia Pharmaceuticals today announced the appointment of Jonathan Emms to the newly-created role of chief operating officer (COO). 12 August 2019
Biotechnology
Nektar Therapeutics lost more than a third of its market value in the opening hours of Friday’s trading. 9 August 2019
Biotechnology
The China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. 9 August 2019
Biotechnology
French biotech DBV Technologies has returned to the US Food and Drug Administration (FDA) with a new Biologics License Application (BLA) for Viaskin Peanut. 9 August 2019
Biotechnology
The self-styled leader in precision genetic medicine for rare diseases suffered a bad turn in the stock market on Thursday. 9 August 2019
Biotechnology
Anglo-Swedish drugmaker AstraZeneca was more than 1.5% up by lunchtime on Friday following the presentation of positive overall survival (OS) results from the Phase III FLAURA trial. 9 August 2019
Biotechnology
The recently-approved CAR-T therapies Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) have come with a price tag to match the level of scientific innovation. 8 August 2019
Biotechnology
As it goes about launching Waylivra (volanesorsen) in Europe, the Ionis Pharmaceuticals affiliate Akcea Therapeutics has announced the publication of data on the rare disease therapy in The New England Journal of Medicine (NEJM). 8 August 2019
Biotechnology
German pharma and crop sciences major Bayer has entered into an agreement to fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. 8 August 2019
Biotechnology
The world’s leading cancer charity has teamed up with Singapore-based Hummingbird Bioscience to develop the company’s anti-HER3 antibody drug, HMBD-001. 8 August 2019
Biotechnology
The US Food and Drug Administration’s Antimicrobial Drugs Advisory Committee (AMDAC) voted by 16 to 2 to recommend approval of Descovy (emtricitabine 200mg and tenofovir alafenamide 25mg tablets; F/TAF) for the proposed indication of pre-exposure prophylaxis (PrEP) in men and transgender women (TGW) who have sex with men. 8 August 2019
Biotechnology
Takeda has submitted a New Drug Application (NDA) in Japan for a subcutaneous (SC) formulation of Entyvio (vedolizumab) as a maintenance therapy for moderately to severely active ulcerative colitis (UC). 8 August 2019
Biotechnology
Rhythm Pharmaceuticals has announced positive top-line results from two pivotal, Phase III clinical trials evaluating setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities. 8 August 2019
Biotechnology
Following the independent Data Monitoring Committee (IDMC) of the PHOCUS trial of Pexa-Vec in liver cancer recommending the study be terminated, French biotech company Transgene said it is currently analyzing the data of the trial it received from its partner SillaJen, notably in the context of the ongoing Phase II clinical trial evaluating the combination regimen of Pexa-Vec and the immunotherapy nivolumab in the same indication. 8 August 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze